Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A β 42 without affecting other A β pools

Journal of Neurochemistry

Volumn 125, Issue 3, 2013, Pages 465-472

  Mitani, Yasuyuki ^a   Yarimizu, Junko ^a   Akashiba, Hiroki ^a   Shitaka, Yoshitsugu ^a   Ni, Keni ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

secretase modulator; A ; Alzheimer's disease; amyloid plaque; APP transgenic mouse; cognition

Indexed keywords

1 [1,1,1 TRIFLUORO 7 METHYLOCTAN 4 YL] 2 [4 [(TRIFLUOROMETHYL)PHENYL]PIPERIDIN 4 YL]ACETIC ACID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

AGE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ANALYSIS;

ACETATES; AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES; CHROMATOGRAPHY, LIQUID; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; HUMANS; MASS SPECTROMETRY; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; PIPERIDINES;

MUS; MUS MUSCULUS;

EID: 84876665764     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12125     Document Type: Article

References (23)

1. Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E., and, Holtzman D. M., (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856-861.
2. Castellano J. M., Kim J., Stewart F. R., et al,. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med., 3, 89ra57.
3. Chang W.-P., Huang X., Downs D., Cirrito J. R., Koelsch G., Holtzman D. M., Ghosh A. K., and, Tang J., (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 25, 775-784.
4. Cirrito J. R., May P. C., O'Dell M. A., et al,. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 8844-8853.
5. Comery T. A., Martone R. L., Aschmies S., et al,. (2005) Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25, 8898-8902.
6. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., and, Van Leuven F., (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390.
7. Fukumoto H., Takahashi H., Tarui N., et al,. (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci. 30, 11157-11166.
8. Garcia Y., Hannam J. C., Harrison T., Hamblett C. L., Hubbs J. L., Kulagowski J. J., Madin A., Ridgill M. P., and, Seward E,. (2007) Piperidines and related compounds for treatment of Alzheimer's disease. In: WO2007/125364.
9. Hall A., Elliott R. L., Giblin G. M. P., Hussain I., Musgrave J., Naylor A., Sasse R., and, Smith B., (2010) Piperidine-derived γ-secretase modulators. Bioorg. Med. Chem. Lett. 20, 1306-1311.
10. Hardy J., and, Selkoe D. J., (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
11. Hong S., Quintero-Monzon O., Ostaszewski B. L., Podlisny D. R., Cavanaugh W. T., Yang T., Holtzman D. M., Cirrito J. R., and, Selkoe D. J., (2011) Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J. Neurosci. 31, 15861-15869.
12. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and, Cole G., (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-103.
13. Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H., and, Younkin S. G., (2001) Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381.
14. Kounnas M. Z., Danks A. M., Cheng S., et al,. (2010) Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769-780.
15. Lue L. F., Kuo Y. M., Roher A. E., et al,. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862.
16. Martone R. L., Zhou H., Atchison K., et al,. (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther. 331, 598-608.
17. McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I., and, Masters C. L., (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
18. Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K., and, Matsuoka N., (2012) Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 2037-2050.
19. Siemers E., Henley D., Sundell K., Sethuraman G., Dean R., Wrobleski K., and, Mohs R., (2011) Evaluating semagacestat, a gamma-secretase inhibitor, in a phase III trial. Alzheimers Dement. 7, S484-S485.
20. Van Broeck B., Chen J. M., Tréton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M., and, Rowley A., (2011) Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 163, 375-389.
21. Weggen S., Eriksen J. L., Das P., et al,. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216.
22. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E., and, Koo E. H., (2003) Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 278, 30748-30754.
23. Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T., and, Selkoe D. J., (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513-517.